SPRY2 and Familial prostate cancer: As previously described in a prostate cancer model, the higher GC-rich dinucleotide percentage near the TSS of SPRY2 renders neighboring CpGs prone to oxidative degradation by sodium bisulfite treatment, in which CG#11207507 resides [22].